

HYBRIGENICS

Hybrigenics patents high doses of inecalcitol

Hybrigenics seeks patent protection until 2029

Paris, June 16th, 2009 - Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris with a focus on the research and development of new cancer treatments and specialized in protein interactions, today announces the filing of a new patent application covering the therapeutic use of high doses of inecalcitol.

The results of the ongoing clinical tolerance Phase II study in hormone-refractory prostate cancer patients demonstrate that daily oral doses as high as 1,000 microgram (microgram), i.e. 1 milligram (mg) of inecalcitol per day, are very well tolerated. In particular, no increase in blood or urinary calcium, the usual dose-limiting toxicity of vitamin D analogues, has been observed. Dose-escalation will next proceed to the 2 mg dose level.

Currently marketed vitamin D analogues for other indications such as rickets, osteoporosis or chronic kidney disease do not exceed 10 micrograms per day. The ability to treat patients with a vitamin D analogue in the milligram dose range is totally new. This makes inecalcitol uniquely suited to reach efficacious levels without side effects in the more challenging cancer indications.

Hybrigenics has filed an application covering this new therapeutic use of high doses of inecalcitol which would extend overall patent protection until 2029. "The fact that we can give at least one milligram of inecalcitol every day without causing hypercalcemia is new and inventive, and can clearly have great therapeutic implications," explained Remi Delansorne, Hybrigenics' CEO. "We believe all patentability conditions are fulfilled, and we therefore decided to file for a new patent to capitalize on the full potential of inecalcitol."

About Hybrigenics (ISIN: FR0004153930, Mnemo: ALHYG)

Hybrigenics (<http://www.hybrigenics.com>) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

HYBRIGENICS

Hybrigenics is also the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

For further information, please contact:

Andrew Lloyd & Associates

Andrew Lloyd / Neil Hunter

Tel: +44 1273 675100

allo@ala.com / neil@ala.com
